TP 0184

Drug Profile

TP 0184

Alternative Names: TP-0184

Latest Information Update: 31 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tolero Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Type II activin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anaemia

Most Recent Events

  • 26 Jan 2017 Tolero Pharmaceuticals has been acquired by Sumitomo Dainippon Pharma
  • 03 Dec 2016 Adverse events, pharmacokinetics and pharmacodynamics data from preclinical studies in Anaemia of chronic disease presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 16 Jun 2015 Preclinical trials in Anaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top